Zealand Pharma Advances Obesity Pipeline With Completed Petrelintide Dose Study

Zealand Pharma A/S (ZLDPF) announced an update on their ongoing clinical study.

Zealand Pharma A/S (ZLDPF) has completed a Phase 1 trial titled “Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations in Participants With a BMI ≥27.0 kg/m².” The study looks at how a single dose of petrelintide behaves in the body at different strengths and how safe it is, offering early signals for its potential as a new obesity treatment.

The treatment under review is petrelintide, also called ZP8396, a drug given as a single injection under the skin. It is designed to support weight management in people who are obese or overweight with related health issues, aiming to join the fast‑growing class of injectable obesity therapies.

This was an interventional, randomized Phase 1 study with four active groups, each receiving a different concentration of petrelintide. There was no placebo and no blinding, and the main purpose was to understand how the drug moves through the body and how different concentrations affect safety rather than to measure weight loss directly.

Participants visited the clinic over about 50 days, with one in‑house stay and repeated blood sampling to track drug levels. The study is listed as completed, and the latest update was posted on April 7, 2026, signaling that data review is advanced and investors should watch for top‑line results and any move toward Phase 2 dose‑finding trials.

For investors, this update reinforces Zealand Pharma’s push into obesity alongside leaders such as Novo Nordisk and Eli Lilly, where valuation often hinges on early drug behavior and safety rather than sales. A clean pharmacokinetic and safety profile could support sentiment in ZLDPF, strengthen partnership prospects, and add optionality to the pipeline, while any tolerability issues could weigh on the stock given intense competition in the GLP‑1 and incretin space.

The study has been completed and recently updated, with full details and any future result postings available on the ClinicalTrials portal.

To learn more about ZLDPF’s potential, visit the Zealand Pharma A/S drug pipeline page.